Treatment of tuberculosis: present status and future prospects.
Over recent years, tuberculosis (TB) and disease caused by human immunodeficiency virus (HIV) have merged in a synergistic pandemic. The number of new cases of TB is stabilizing and declining, except in countries with a high prevalence of HIV infection. In these countries, where HIV is driving an in...
| Publicado en: | Bulletin of the World Health Organization Vol. 83; no. 11; pp. 857 - 866 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
World Health Organization
Nov2005
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106090604&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106090604 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00429686 BUW jtl: Bulletin of the World Health Organization issn: 00429686 maglogo: N pubinfo: dt: Nov2005 vid: 83 iid: 11 pid: 437 pub: World Health Organization artinfo: ui: 106090604 106090604 2009425555 NLM16302043 106090604 ppf: 857 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Treatment of tuberculosis: present status and future prospects. aug: au: Onyebujoh P Zumla A Ribeiro I Rustomjee R Mwaba P Gomes M Grange JM sug: subj: Antitubercular Agents Therapeutic Use Protocols Tuberculosis Drug Therapy Antitubercular Agents Adverse Effects HIV Infections Complications Public Health Tuberculosis Etiology ab: Over recent years, tuberculosis (TB) and disease caused by human immunodeficiency virus (HIV) have merged in a synergistic pandemic. The number of new cases of TB is stabilizing and declining, except in countries with a high prevalence of HIV infection. In these countries, where HIV is driving an increase in the TB burden, the capacity of the current tools and strategies to reduce the burden has been exceeded. This paper summarizes the current status of TB management and describes recent thinking and strategy adjustments required for the control of TB in settings of high HIV prevalence. We review the information on anti-TB drugs that is available in the public domain and highlight the need for continued and concerted efforts (including financial, human and infrastructural investments) for the development of new strategies and anti-TB agents. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|